Meeting
2023 ASCO Annual Meeting
Effect of homologous recombination deficient (HRD) breast cancers on a distinct immune marker phenotype by comprehensive genomic and immune profiling (CGIP).
Authors
Heidi Chwan Ko
Labcorp Oncology, Durham, NC
Heidi Chwan Ko , Sarabjot Pabla , Mary K Nesline , Kyle C Strickland , Rebecca A. Previs , Zachary D Wallen , Shengle Zhang , Jeffrey M. Conroy , Mark Sausen , Jennifer B Jackson , Kamal S. Saini , Scott Wise , Taylor J. Jensen , Venkataprasanth P. Reddy , Eric A Severson , Shakti Ramkissoon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1029)
DOI
10.1200/JCO.2023.41.16_suppl.1029
Abstract #
1029
Poster Bd #
250
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan
Poster
2022 ASCO Annual Meeting
Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay.
First Author: Jonathan Poh
Poster
2020 Gastrointestinal Cancers Symposium
Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients (pts) with pancreatic adenocarcinoma (PC): A single institution experience.
First Author: Amy E. Chang
Poster
2020 Gastrointestinal Cancers Symposium
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.
First Author: Thomas J. George